Scarica l'app Stockscreener
7.58
0.92%
-0.07
Dopo l'orario di chiusura:
7.58
Precedente Chiudi:
$7.65
Aprire:
$7.54
Volume 24 ore:
677.28K
Relative Volume:
0.49
Capitalizzazione di mercato:
$490.32M
Reddito:
$202.09M
Utile/perdita netta:
$-61.69M
Rapporto P/E:
-7.0185
EPS:
-1.08
Flusso di cassa netto:
$-35.64M
1 W Prestazione:
+4.84%
1M Prestazione:
-20.46%
6M Prestazione:
-46.09%
1 anno Prestazione:
-52.21%
Intervallo 1D:
$7.42
$7.70
Intervallo di 1 settimana:
$7.165
$7.95
Portata 52W:
$5.71
$17.82
Evolus Inc Stock (EOLS) Company Profile
Nome
Evolus Inc
Settore
Telefono
(949) 284-4555
Indirizzo
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Confronta EOLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
7.58 | 494.84M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
155.37 | 68.60B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.86 | 46.99B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.71 | 43.17B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.05 | 20.82B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
305.35 | 13.98B | 2.99B | 1.21B | 1.13B | 25.06 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Downgrade | Needham | Buy → Hold |
| 2025-04-17 | Iniziato | BTIG Research | Buy |
| 2024-01-29 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-06-23 | Iniziato | Needham | Buy |
| 2022-05-12 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-20 | Aggiornamento | Truist | Hold → Buy |
| 2021-05-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-04-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-24 | Downgrade | Truist | Buy → Hold |
| 2020-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2020-02-06 | Ripresa | Mizuho | Buy |
| 2019-11-26 | Iniziato | SVB Leerink | Outperform |
| 2019-09-05 | Ripresa | Mizuho | Buy |
| 2019-06-28 | Iniziato | Wells Fargo | Market Perform |
| 2019-06-11 | Iniziato | Barclays | Underweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-02-14 | Iniziato | H.C. Wainwright | Buy |
| 2019-01-29 | Iniziato | Stifel | Buy |
Mostra tutto
Evolus Inc Borsa (EOLS) Ultime notizie
Tools to monitor Evolus Inc. recovery probabilityJuly 2025 Outlook & Long-Term Investment Growth Plans - Newser
Is a relief rally coming for Evolus Inc. holdersBull Run & Risk Controlled Swing Trade Alerts - Newser
How to interpret RSI for Evolus Inc. stock2025 Trading Recap & Consistent Growth Stock Picks - Newser
Price action breakdown for Evolus Inc.Portfolio Risk Report & High Return Trade Opportunity Guides - Newser
Multi factor analysis applied to Evolus Inc.Weekly Profit Analysis & Free Daily Entry Point Trade Alerts - Newser
Can trapped investors hope for a rebound in Evolus Inc.Portfolio Return Summary & Weekly Momentum Picks - Newser
What indicators show strength in Evolus Inc.July 2025 Recap & Advanced Technical Signal Analysis - Newser
Evolus CMO Tomoko Yamagishi-Dressler Sells 5,722 Shares at $7.51/Share on 2025-08-22 - AInvest
Using Bollinger Bands to evaluate Evolus Inc.2025 Market Outlook & Community Verified Trade Alerts - Newser
Short Interest Drops in Evolus Inc. After Rally getLinesFromResByArray error: size == 0 - kangso.co.kr
Visual analytics tools that track Evolus Inc. performance2025 Top Decliners & Free Risk Controlled Daily Trade Plans - Newser
Applying big data sentiment scoring on Evolus Inc.2025 Market Sentiment & Safe Entry Zone Tips - Newser
Understanding Evolus Inc.’s price movementWeekly Earnings Recap & Daily Oversold Bounce Ideas - Newser
Evolus Submits Evolysse Sculpt for FDA Approval, Expanding HA Dermal Filler Portfolio - newbeauty.com
Evolus announces Evolysse Sculpt trial meets primary endpoint - TipRanks
Evolus announces positive results for Evolysse Sculpt study - MarketScreener
Evolus Announces Positive Data from Pivotal Trial for Evolysse Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp - MarketScreener
Has Evolus Inc. found a price floorEntry Point & Fast Moving Market Watchlists - Newser
Will Evolus Inc. bounce back from current support2025 Macro Impact & Capital Protection Trading Alerts - Newser
What are the risks of holding Evolus Inc.July 2025 Movers & Safe Entry Momentum Stock Tips - theviewers.co.kr
Applying chart zones and confluence areas to Evolus Inc.Trade Performance Summary & High Win Rate Trade Alerts - Newser
Is Evolus Inc. stock trending bullishJuly 2025 Institutional & Verified Technical Trade Signals - theviewers.co.kr
Identifying reversal signals in Evolus Inc.July 2025 Sentiment & Community Verified Trade Alerts - Newser
Short Interest Drops in Evolus Inc. After RallyEarnings Overview Report & Verified Chart Pattern Signals - beatles.ru
Evolus Inc. Pullback Analyzed — Is It Time to ExitJuly 2025 Breakouts & Risk Adjusted Buy and Sell Alerts - beatles.ru
Evolus Inc. Volume Confirms Breakout — Analysts BullishJuly 2025 Action & AI Based Buy and Sell Signals - 더경남뉴스
Mizuho reiterates Outperform rating on Evolus stock, maintains $19 target - Investing.com
Mizuho reiterates Outperform rating on Evolus stock, citing valuation - Investing.com
Brady Stewart Bought 59% More Shares In Evolus - simplywall.st
Evolus submits Evolysse premarket approval application to FDA - TipRanks
Latest Company News - Investing.com
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse?? Sculpt Injectable Hyaluronic Acid Gel Product - MarketScreener
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product - Business Wire
Evolus plunges after Q2 miss, guidance cut; Needham downgrades - MSN
Director’s Bold Move: Major Stock Purchase Signals Confidence in Evolus - TipRanks
Evolus Sees Aesthetic Market Slowing After Q2 Miss - Orange County Business Journal
News impact scoring models applied to Evolus Inc.July 2025 Breakouts & Expert-Curated Trade Recommendations - Newser
Using data filters to optimize entry into Evolus Inc.Weekly Profit Recap & Verified Trade Idea Suggestions - Newser
Is Evolus Inc. stock technically oversold2025 Trading Volume Trends & Low Drawdown Momentum Trade Ideas - thegnnews.com
Is Evolus Inc. Forming a Consolidation BaseJuly 2025 Recap & Trade Opportunity Analysis - metal.it
Live Scanner Shows Breakout on Evolus Inc.Jobs Report & Verified High Yield Trade Plans - 선데이타임즈
Evolus announces commercial launch of Evolysse - MSN
Midday Stock Roundup: ICU Medical Soars, Willdan Group Down - Orange County Business Journal
Is This the Dip to Buy in Evolus Inc.July 2025 Pullbacks & Capital Protection Trade Alerts - metal.it
Resistance Break Could Fuel Evolus Inc. Rally2025 Risk Factors & High Accuracy Swing Entry Alerts - classian.co.kr
Evolus Inc Azioni (EOLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
1.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):